A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Venetoclax (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 15 Aug 2024 Planned End Date changed from 4 Sep 2024 to 21 Mar 2026.
- 15 Aug 2024 Planned primary completion date changed from 4 Sep 2024 to 21 Mar 2026.
- 18 Jun 2024 Planned End Date changed from 2 Mar 2024 to 4 Sep 2024.